Montelukast Doc

Montelukast, the active ingredient in Montelukast Doc, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in patients who require control of airway inflammation and bronchospasm.

GNH USA supplies Montelukast Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma: improves long‑term control and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic inflammation.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain or dyspepsia: occasional discomfort. - Mood changes: irritability or mild anxiety.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, suicidal thoughts, or hallucinations. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before initiating therapy, consider the following precautions. - Pregnancy: Category B – use only if clearly needed after risk‑benefit assessment. - Breastfeeding: small amounts excreted in milk; weigh benefits to infant against potential risk. - Hepatic impairment: monitor liver function in patients with pre‑existing liver disease. - Concomitant asthma therapy: do not replace inhaled corticosteroids or bronchodilators without medical guidance. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Montelukast may interact with several drug classes.

Major Interactions (Avoid): - Phenobarbital or rifampin: may reduce montelukast plasma concentrations, compromising efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase exposure, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Antidepressants (SSRIs, SNRIs): potential additive neuropsychiatric effects; observe mood changes.